Cyclosporine-induced autologous graft-versus-host disease following autologous blood stem cell transplantation for lymphoma.
Eight consecutive patients with relapsed/refractory non-Hodgkin's lymphoma or Hodgkin's disease received conditioning therapy with BCNU, etoposide, cytosine arabinoside and melphalan (BEAM) followed by autologous blood stem cell transplantation (ABSCT). Cyclosporine was administered from day +1 until day +28 post-ABSCT to induce autologous graft-versus-host disease (GVHD) for a possible antitumor effect. Three patients developed histologically documented grade II GVHD between 22-40 days post-transplant. GVHD resolved with local hydrocortisone 1% application in one patient and after a short course of steroid in the remaining two patients. Further studies are required to document any beneficial antitumor effect of such therapy following ABSCT.
Pati
A R
AR
Division of Transplantation Medicine, Richland Memorial Hospital, University of South Carolina, Columbia, USA.
Godder
K T
KT
Abhyankar
S H
SH
Gee
A P
AP
Henslee-Downey
P J
PJ
D000328:Adult; D016572:Cyclosporine / Q000494:pharmacology*; D005260:Female; D006086:Graft vs Host Disease / Q000139:chemically induced*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous
D007166:Immunosuppressive Agents; D016572:Cyclosporine